Similarly, bispecific antibodies targeting CD40 or CD1d have shown success in preclinical models of hematological malignancies, such as chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) [97,98]. This evidence concerns the gene CD1D and B-cell chronic lymphocytic leukemia.